Frenia 1 mg Tablet is an atypical antipsychotic designed for the treatment of schizophrenia, bipolar disorder, and other psychotic conditions. It helps manage both positive symptoms of psychosis, such as hallucinations, delusions, and hostility, and negative symptoms, including emotional withdrawal, blunted affect, and reduced speech. Frenia also alleviates affective symptoms like anxiety, depression, and guilt associated with schizophrenia. In addition, it is effective in maintaining clinical improvement during continuation therapy and managing manic episodes in bipolar disorder.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Frenia 1 mg is indicated for:
Acute and chronic schizophrenic psychoses
Other psychotic disorders with prominent positive and/or negative symptoms
Alleviation of affective symptoms associated with schizophrenia
Continuation therapy in patients responding to initial treatment
Management of manic episodes in bipolar disorder
Atypical Neuroleptic Drugs
Frenia 1 mg is a selective monoaminergic antagonist with a high affinity for:
Serotonin 5-HT2 receptors
Dopamine D2 receptors
It also binds to alpha1 adrenergic receptors and, to a lesser extent, H1 histamine and alpha2 adrenergic receptors, while showing no affinity for cholinergic receptors.
By antagonizing D2 receptors, Frenia improves positive symptoms without significantly depressing motor activity. Its balanced serotonin-dopamine antagonism may reduce the risk of extrapyramidal side effects and extends therapeutic effects to negative and affective symptoms of schizophrenia.
Psychoses:
Day 1: 2 mg in 1–2 divided doses
Day 2: 4 mg in 1–2 divided doses
Usual dose: 4–6 mg daily
Maximum: 16 mg daily (only if benefits outweigh risks)
Elderly or hepatic/renal impairment:
Start at 1 mg daily in two divided doses; increase gradually in 1–2 mg increments
Mania:
Initial dose: 2 mg once daily; titrate by 1 mg daily as needed
Usual range: 1–6 mg daily
Schizophrenia:
Start with 1 mg twice daily
Increase by 1 mg BID over the first 2–3 days to a target of 3 mg BID
Adjustments should occur at intervals of at least 1 week, with small increments/decrements of 1–2 mg
May antagonize levodopa and dopamine agonists
Chronic use with carbamazepine reduces Frenia clearance
Chronic use with clozapine may decrease Frenia clearance
May enhance the effects of certain antihypertensives
Hypersensitivity to Frenia or any of its components
Common adverse effects include:
Insomnia, agitation, anxiety, headache
Less common: drowsiness, impaired concentration, fatigue, blurred vision, constipation, nausea, vomiting, dyspepsia, abdominal pain
Others: hyperprolactinemia, urinary incontinence, tachycardia, hypertension, edema, rash, rhinitis, cerebrovascular events, neutropenia, thrombocytopenia
Pregnancy: Safety not established; animal studies show no teratogenicity but some prolactin- and CNS-mediated effects
Lactation: Excreted in human breast milk; breastfeeding is not recommended
Use cautiously in patients with cardiovascular disease, renal or hepatic impairment, epilepsy, Parkinson’s disease, and in elderly patients
Monitor for signs of tardive dyskinesia and discontinue if symptoms occur
Exercise caution during pregnancy
Symptoms: drowsiness, sedation, tachycardia, hypotension, and extrapyramidal effects. Severe cases may require anticholinergic treatment and close medical monitoring. No specific antidote is available.
Store in a cool, dry place, protected from light.
Login Or Registerto submit your questions to seller
No none asked to seller yet